{'fraction_non_alphanumeric': 0.01048951048951049, 'fraction_numerical': 0.0, 'mean_word_length': 6.346153846153846, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Immunotherapeutics for nosocomial infections

Nosocomial or hospital-acquired infections are associated with prolonged hospitalisation and increased healthcare costs and resource utilisation. Continued advances in sophisticated medical procedures, an increase in the number of immunocompromised patients and a steady rise in the prevalence of antibiotic-resistant organisms has renewed interest in the development of novel therapies that can treat nosocomial infections. This review focuses on novel immunological approaches to address this significant unmet medical need.